The E3 ubiquitin ligase NEDD4 negatively regulates HER3/ErbB3 level and signaling
1Texas Therapeutics Institute, Brown Foundation Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX, USA.
Abstract:
HER3/ErbB3, a member of the epidermal growth factor receptor (EGFR) family, has a pivotal role in cancer and is emerging as a therapeutic antibody target. In this study, we identified NEDD4 (neural precursor cell expressed, developmentally downregulated 4) as a novel interaction partner and ubiquitin E3 ligase of human HER3. Using molecular and biochemical approaches, we demonstrated that the C-terminal tail of HER3 interacted with the WW domains of NEDD4 and the interaction was independent of neuregulin-1. Short hairpin RNA knockdown of NEDD4 elevated HER3 levels and resulted in increased HER3 signaling and cancer cell proliferation in vitro and in vivo. A similar inverse relationship between HER3 and NEDD4 levels was observed in prostate cancer tumor tissues. More importantly, the upregulated HER3 expression by NEDD4 knockdown sensitized cancer cells for growth inhibition by an anti-HER3 antibody. Taken together, our results suggest that low NEDD4 levels may predict activation of HER3 signaling and efficacies of anti-HER3 antibody therapies.
Insights
Neural precursor cell expressed, developmentally downregulated 4 (NEDD4) ubiquitin ligase targets HER3/ErbB3. Low NEDD4 levels increase HER3 signaling and cancer growth, predicting anti-HER3 antibody therapy efficacy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- HER3/ErbB3 is a key cancer driver and therapeutic target.
- Understanding HER3 regulation is crucial for cancer therapy.
Purpose of the Study:
- Identify novel regulators of HER3.
- Investigate the role of NEDD4 in HER3 signaling and cancer.
Main Methods:
- Molecular and biochemical assays to study HER3-NEDD4 interaction.
- Short hairpin RNA (shRNA) knockdown of NEDD4 in cancer cells.
- In vitro and in vivo proliferation assays.
- Analysis of patient tumor tissues.
Main Results:
- NEDD4 directly interacts with HER3 via its WW domains.
- NEDD4 knockdown increases HER3 levels, signaling, and cancer cell proliferation.
- Inverse correlation between HER3 and NEDD4 expression in prostate cancer.
- NEDD4 knockdown enhances sensitivity to anti-HER3 antibodies.
Conclusions:
- NEDD4 is a novel ubiquitin E3 ligase for HER3.
- Low NEDD4 expression correlates with HER3 activation and increased cancer proliferation.
- NEDD4 levels may predict response to anti-HER3 antibody therapies.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Export of Misfolded Proteins out of the ER
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Mitogens and the Cell Cycle
Negative Regulator Molecules


